American Regent v. Somerset Therapeutics: Selenious Acid ANDA Litigation Consolidated
American Regent, Inc. filed suit against Somerset Therapeutics, LLC, Somerset Pharma, LLC, and Odin Pharmaceuticals, LLC in the District of New Jersey, asserting US11998565B2 covering its Selenious Acid Injection (600 mcg Selenium/10 mL) against a proposed generic entrant. The case was consolidated within 128 days into a coordinated 13-defendant ANDA action — one of the largest multi-defendant selenious acid patent disputes on record.
Hatch-Waxman wave: ARI’s 13-front selenious acid patent defence
On July 16, 2024, American Regent, Inc. filed this action in the U.S. District Court for the District of New Jersey against Somerset Therapeutics, LLC, Somerset Pharma, LLC, and Odin Pharmaceuticals, LLC, asserting infringement of US11998565B2 in connection with defendants’ ANDA filing for a generic version of ARI’s Selenious Acid Injection, USP (600 mcg Selenium/10 mL). The patent covers the formulation and composition of ARI’s branded intravenous selenium product, a critical trace element supplement used in parenteral nutrition.
On October 22, 2024 — just 98 days after filing — the parties jointly moved to consolidate this action with twelve parallel ANDA suits filed by ARI against defendants including Accord Healthcare, Cipla, Dr. Reddy’s, Hikma, Sun Pharmaceutical, and Zydus, among others. The court consolidated all 13 cases under lead docket No. 2:24-cv-07791, with all future filings to proceed under that caption. Consolidation is a procedural mechanism, not a merits disposition; no liability finding or dismissal has occurred.
The 128-day timeline from filing to consolidation is consistent with coordinated Hatch-Waxman strategy, where brand-name holders simultaneously sue multiple ANDA filers to trigger the 30-month stay and consolidate discovery. The breadth of defendants — spanning domestic generics, Indian pharma groups, and specialty formulators — suggests ARI received paragraph IV certifications from a large cohort simultaneously, a pattern typical of competitive parenteral nutrition markets. The ultimate merits of the ‘565 patent’s validity and infringement remain unresolved and will be litigated in the consolidated proceeding.
Filing to Case Consolidated in 128 days
128 days to consolidation — markedly faster than typical ANDA case resolution, suggesting procedural efficiency was prioritised early
What consolidation means: one docket, 13 defendants, live patent dispute
Consolidation is procedural — not a merits ruling
Case consolidation under Fed. R. Civ. P. 42(a) allows a court to join related actions sharing common questions of law or fact. Here, all 13 ANDA suits involve the same patent (US11998565B2) and the same reference product. No findings on validity or infringement have been made. All claims survive and will be adjudicated together under lead case 2:24-cv-07791.
No merits dispositionARI gains litigation efficiency across 13 ANDA filers
Consolidation benefits American Regent by centralising discovery, claim construction, and any validity challenges into a single proceeding. This reduces duplication of expert testimony and briefing costs. Critically, each individual suit filing still triggers a separate 30-month Hatch-Waxman stay against the respective ANDA applicant, preserving ARI’s market exclusivity window during litigation.
30-month stay preservedSomerset and co-defendants face coordinated patent challenge
Somerset Therapeutics, Somerset Pharma, and Odin Pharmaceuticals now litigate alongside 10 other generic challengers. Consolidation may align their invalidity and non-infringement arguments with co-defendants, potentially sharing costs. However, each defendant’s FDA approval timeline remains individually at risk under the 30-month stay triggered by ARI’s individual suit filings.
Shared invalidity strategy likelyParenteral selenium market entry delayed pending outcome
With 13 ANDA applicants blocked by litigation, ARI effectively controls the near-term competitive landscape for Selenious Acid Injection USP. Generic entry for all named defendants is contingent on either a successful patent challenge or expiry. The consolidated structure suggests this case will proceed to claim construction and likely summary judgment or trial, making it a high-stakes bellwether for the parenteral nutrition generic market.
Generic entry delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer — holder of US11998565B2 covering Selenious Acid Injection USPSearch in Eureka ↗ |
| Defendant | Somerset Therapeutics, LLC | Company | Generic pharmaceutical entities: Somerset Therapeutics LLC, Somerset Pharma LLC, and Odin Pharmaceuticals LLCSearch in Eureka ↗ |
| Co-Defendant | Odin Pharmaceuticals, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Somerset Pharma, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Somerset Therapeutics, LLCSearch in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Somerset Therapeutics, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order recites each of the 13 parallel civil actions filed by ARI and states that ‘good cause exists to consolidate these actions,’ directing all filings to proceed under lead case No. 2:24-cv-07791. The order is purely procedural in scope — it makes no findings on infringement, validity, or enforceability of US11998565B2. For Somerset and its co-defendants, consolidation means their individual cases are absorbed into a coordinated proceeding where claim construction rulings and any invalidity findings will have binding effect across all 13 defendants simultaneously.
US11998565B2 — Selenious Acid Injection USP formulation patent
US11998565B2 protects American Regent’s Selenious Acid Injection, USP — a 600 mcg selenium per 10 mL (60 mcg/mL) intravenous formulation used in parenteral nutrition to supplement selenium in patients who cannot receive adequate oral nutrition. The application number US18/124391 indicates prosecution was completed relatively recently, suggesting the patent covers formulation-specific innovations rather than the selenium compound itself, which is long off patent. The precise scope of claims — whether directed to concentration, excipient composition, container type, or manufacturing process — will be central to the consolidated litigation.
Selenious acid injections occupy a niche but clinically essential segment of the parenteral nutrition market. ARI’s decision to assert this patent simultaneously against 13 generic filers signals that it views the ‘565 patent as a robust blocking position. For any company developing or supplying IV selenium products, this patent is now the primary freedom-to-operate risk. The consolidated litigation will likely produce a claim construction ruling that sets the de facto industry standard for what constitutes infringing selenium injection formulations — making the outcome commercially significant well beyond the named defendants.
Should your IV nutrition pipeline require an FTO against US11998565B2?
Any company developing, manufacturing, or distributing a generic or biosimilar selenious acid injection — particularly at the 60 mcg/mL concentration — should treat US11998565B2 as a live blocking patent until the consolidated NJ litigation resolves. The 13-defendant case confirms ARI is actively enforcing, and the 30-month stays mean FDA approval alone will not guarantee market access. R&D teams reformulating or repackaging IV selenium products for pharmacy bulk package distribution should conduct a formal FTO analysis before committing to ANDA filings.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US11998565B2 against your product specifications, surface relevant prior art that co-defendants may use in invalidity challenges, and flag related continuation or divisional applications in ARI’s portfolio that could extend the blocking window. Monitoring the consolidated docket for claim construction orders will be essential — Eureka’s litigation tracking tools allow R&D and IP teams to receive real-time alerts as the case progresses.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Related Hatch-Waxman ANDA patent cases in parenteral nutrition
Explore parallel ANDA infringement actions involving intravenous formulation patents litigated in the District of New Jersey, including co-pending ARI cases under lead docket 24-7791.
What this case signals for the parenteral nutrition IP landscape
ARI’s coordinated 13-defendant filing is a deliberate Hatch-Waxman enforcement strategy that every generic pharma team in the IV nutrition space should monitor closely.
Simultaneous paragraph IV filings trigger coordinated brand-side response
When multiple ANDAs include paragraph IV certifications against the same patent, brand holders routinely file parallel suits to capture 30-month stays against each applicant. ARI’s 13 simultaneous filings are textbook execution of this strategy, signalling confidence in US11998565B2’s enforceability and a determination to delay all generic entrants in parallel.
Consolidation accelerates claim construction — watch for early Markman hearing
Consolidated ANDA proceedings in the District of New Jersey typically move toward a Markman claim construction hearing within 12–18 months. The outcome of claim construction will be pivotal for all 13 defendants: a narrow construction of the ‘565 patent’s formulation claims could open design-around opportunities, while a broad construction strengthens ARI’s blocking position across the board.
American v Somerset — key questions answered
The case was consolidated on October 22, 2024 into a 13-defendant coordinated ANDA proceeding under lead case No. 2:24-cv-07791. This is a procedural outcome only — no merits ruling on infringement or validity of US11998565B2 has been issued. All substantive claims remain pending in the consolidated action.
American Regent asserts US11998565B2 (application No. US18/124391), covering its Selenious Acid Injection, USP (600 mcg Selenium/10 mL; 60 mcg/mL), across all 13 consolidated ANDA cases filed in the District of New Jersey in July 2024.
Consolidation under Fed. R. Civ. P. 42(a) means Somerset’s case is managed alongside 12 other ANDA defendants. Somerset retains its individual claims and defences, but will share discovery, claim construction proceedings, and likely briefing schedules with co-defendants. ARI’s 30-month Hatch-Waxman stay against Somerset’s ANDA remains independently in effect.
The 13 consolidated cases name: Accord Healthcare; Aspiro Pharma; Cipla USA and Cipla Limited; Dr. Reddy’s Laboratories; Eugia Pharma and Eugia US; Gland Pharma; Hikma Pharmaceuticals USA; Long Grove Pharmaceuticals; RK Pharma; Somerset Therapeutics, Somerset Pharma, and Odin Pharmaceuticals; Sun Pharmaceutical; Xiromed; and Zydus Pharmaceuticals.
US11998565B2 is the primary IP barrier to generic entry in the Selenious Acid Injection USP market at the 60 mcg/mL concentration. With 13 ANDA applicants blocked by concurrent litigation and 30-month stays, ARI effectively controls near-term competitive access. The patent’s claim construction outcome in the consolidated NJ proceeding will set the industry standard for what formulations infringe, making it a high-stakes ruling for all IV nutrition generic manufacturers.
PatSnap Eureka searches patents and litigation data to answer instantly.